Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

OCGN – Ocugen, Inc.

Float Short %

19.21

Margin Of Safety %

Put/Call OI Ratio

0.06

EPS Next Q Diff

0.01

EPS Last/This Y

-0.03

EPS This/Next Y

-0.01

Price

1.2

Target Price

9

Analyst Recom

1

Performance Q

16.5

Relative Volume

0.54

Beta

3.51

Ticker: OCGN




19 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2025-11-10OCGN1.340.100.1670243
2025-11-11OCGN1.3250.100.0070399
2025-11-12OCGN1.3250.100.0270494
2025-11-13OCGN1.2250.100.0470411
2025-11-14OCGN1.1950.100.0170561
2025-11-17OCGN1.160.100.0470907
2025-11-18OCGN1.140.100.0271334
2025-11-19OCGN1.1350.100.0771688
2025-11-20OCGN1.10.100.0571878
2025-11-21OCGN1.160.100.0572337
2025-11-24OCGN1.190.060.0061175
2025-11-25OCGN1.160.060.1161615
2025-11-26OCGN1.1850.060.0062094
2025-12-01OCGN1.1850.060.0265536
2025-12-02OCGN1.160.060.1165868
2025-12-03OCGN1.2050.060.0566296
2025-12-04OCGN1.240.060.0066632
2025-12-05OCGN1.220.060.0467127
2025-12-08OCGN1.20.060.0167727
DateSymbolLatestP/C OIP/C VolTotal OI
19 items Current Page1 of 1




19 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-11-10OCGN1.35-15.0- -0.21
2025-11-11OCGN1.33-15.0- -0.21
2025-11-12OCGN1.33-15.0- -0.21
2025-11-13OCGN1.23-15.0- -0.21
2025-11-14OCGN1.20-20.0- -0.23
2025-11-17OCGN1.15-20.0- -0.23
2025-11-18OCGN1.14-20.0- -0.23
2025-11-19OCGN1.14-20.0- -0.23
2025-11-20OCGN1.10-20.0- -0.23
2025-11-21OCGN1.15-20.0- -0.23
2025-11-24OCGN1.19-20.0- -0.23
2025-11-25OCGN1.17-20.0- -0.23
2025-11-26OCGN1.19-20.0- -0.23
2025-12-01OCGN1.19-15.0- -0.23
2025-12-02OCGN1.16-15.0- -0.23
2025-12-03OCGN1.21-15.0- -0.23
2025-12-04OCGN1.25-15.0- -0.23
2025-12-05OCGN1.22-15.0- -0.23
2025-12-08OCGN1.20-15.0- -0.23
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
19 items Current Page1 of 1




19 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-11-10OCGN0.00-7.2518.91
2025-11-11OCGN0.00-7.2518.91
2025-11-12OCGN0.00-7.2518.88
2025-11-13OCGN0.00-7.2518.88
2025-11-14OCGN0.00-7.2518.88
2025-11-17OCGN0.00-0.6118.86
2025-11-18OCGN0.00-0.6118.86
2025-11-19OCGN0.00-0.6118.86
2025-11-20OCGN0.00-0.6118.86
2025-11-21OCGN0.00-0.6118.86
2025-11-24OCGN0.00-1.9918.86
2025-11-25OCGN0.00-1.9918.86
2025-11-26OCGN0.00-1.9919.21
2025-12-01OCGN0.00-1.9719.21
2025-12-02OCGN0.00-1.9719.21
2025-12-03OCGN0.00-1.9719.21
2025-12-04OCGN0.00-1.9719.21
2025-12-05OCGN0.00-1.9719.21
2025-12-08OCGN0.00-2.0019.21
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
19 items Current Page1 of 1

Last Quarter Act. EPS

-0.07

Avg. EPS Est. Current Quarter

-0.06

Avg. EPS Est. Next Quarter

-0.06

Insider Transactions

Institutional Transactions

-2

Beta

3.51

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

3

Growth Score

26

Sentiment Score

41

Actual DrawDown %

93.6

Max Drawdown 5-Year %

-97.7

Target Price

9

P/E

Forward P/E

PEG

P/S

69.79

P/B

106.1

P/Free Cash Flow

EPS

-0.22

Average EPS Est. Cur. Y​

-0.23

EPS Next Y. (Est.)

-0.24

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-1192.22

Relative Volume

0.54

Return on Equity vs Sector %

-1838.9

Return on Equity vs Industry %

-1824

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.02

EBIT Estimation

Ocugen, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 95
Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is involved in the development of OCU200, a novel fusion protein for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.
stock quote shares OCGN – Ocugen, Inc. Stock Price stock today
news today OCGN – Ocugen, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch OCGN – Ocugen, Inc. yahoo finance google finance
stock history OCGN – Ocugen, Inc. invest stock market
stock prices OCGN premarket after hours
ticker OCGN fair value insiders trading